Tuesday, June 18, 2013

Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) collaborate for development of Ambrx HER2+ve breast cancer compound

US based Ambrx which specializes in protein therapeutics has entered into a collaboration with China based Zhejiang Medicine Co. Ltd. (ZMC) for the development and commercialization of  ARX788 which is Ambrx's most advanced internally developed site specific antibody drug conjugate (ADC) targeting Her2-positive breast cancer.

Under the agreement, Ambrx and ZMC will continue the development of ARX788, with ZMC bearing the ongoing development cost. ZMC will receive commercial rights in China while Ambrx retains commercial rights outside of China and receives royalties on sales of the product in China. Zhejiang Medicine company will manufacture the product to world-class standards for clinical and commercial supplies on a global basis. WuXi PharmaTech will provide integrated services for ARX788, including the development and manufacturing of the toxin, antibody and ADC, pre-clinical development and clinical trials.